LENSAR Inc(LNSR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.33 | Insider Own | 19.9% | Shs Outstand | 12.3M | Perf Week | -3.79% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | -2350% | Insider Trans | - | Shs Float | 9.8M | Perf Month | -11.11% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.1 | Inst Own | 45.1% | Short Float | 3.12% | Perf Quarter | 8.55% |
| Income | 0.02B | P/S | 1.19 | EPS this Y | 100.35% | Inst Trans | -8.13% | Short Ratio | 2.94 | Perf Half Y | 4.1% |
| Sales | 0.06B | P/B | 4.81 | EPS next 5Y | - | ROA | 22.16% | Short Interest | 0.31M | Perf YTD | -49.79% |
| Book/sh | 1.21 | P/C | 5.29 | EPS past 3/5Y | -13.51% -9.65% | ROE | 159.72% | 52W High | -54.87% ($12.94) | Perf Year | -51.54% |
| Cash/sh | 1.1 | P/FCF | - | Sales past 3/5Y | 18.23% 17.24% | ROIC | 51.23% | 52W Low | 17.98% ($4.95) | Perf 3Y | 171.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 130.18% | Gross Margin | 46.82% | Volatility(W/M) | 2.88% 3.33% | Perf 5Y | -18.32% |
| Dividend TTM | - | EV/Sales | 1.23 | Sales Y/Y TTM | 3.26% | Oper. Margin | -13.48% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.13 | EPS Q/Q | 167.73% | Profit Margin | 25.74% | RSI (14) | 34.57 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.39 | Sales Q/Q | 18.37% | SMA20 | -4.34% ($6.1) | Beta | 1.02 | Target Price | $11.33 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/8/13 | SMA50 | -17.77% ($7.1) | Rel Volume | 0.28 | Prev Close | $5.97 |
| Employees | 150 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 160.61% 12.59% | SMA200 | -21.64% ($7.45) | Avg Volume(3M) | 0.10M | Price | $5.84 |
| IPO | 2020/10/2 | Option/Short | Yes/Yes | Trades | 329 | Volume | 28,839 | Change | -2.18% |
An innovative company in the laser ophthalmic surgery systems field, leading global surgical precision through its AI- and robotics-powered cataract surgery platform ALLY®.
Over the past 1 year, on the lower side
55% below its 1-year high.
Traded less than usual. That is 28% of its average volume.
LNSR has a sound balance sheet but weak earning power
Of every $100 in sales, $13.48 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +100.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $119. Peers typically go for $143.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -18.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 45.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #92 of 142 in the industry
Based on market cap of $72M.
FAQ
What kind of company is LNSR?
LNSR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of LNSR?
The market cap of LNSR is approximately $72M, ranking 4,671 within its sector.
What is the 52-week high and low for LNSR?
LNSR has recorded a 52-week high of $12.94 and a low of $4.95.
